Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Analyst Ratings
Hold
5 Buy
10 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BMY Stock 12 Month Forecast
Average Price Target
$60.93
▲(2.90% Upside)
| Highest Price Target$70.00 | Average Price Target$60.93 | Lowest Price Target$37.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
Reiterated
03/20/25
Morgan Stanley
Reiterated
03/12/25
William Blair
Reiterated
03/11/25
Leerink Partners
Reiterated
03/10/25
Berenberg Bank
Reiterated
03/07/25
Wells Fargo
Reiterated
02/20/25
Bernstein
Reiterated
02/20/25
Truist Financial
Reiterated
02/20/25
BMO Capital
Reiterated
02/19/25
Deutsche Bank
$55→$53
Hold
-10.49%
Downside
Reiterated
02/10/25
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche BankDeutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.
Goldman Sachs
$65→$67
Buy
13.16%
Upside
Reiterated
02/07/25
Bristol-Myers Squibb Co. (BMY) PT Raised to $67 at Goldman SachsGoldman Sachs analyst Chris Shibutani raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $67.00 (from $65.00) while maintaining a Buy rating.
Bank of America Securities
$63
Hold
6.40%
Upside
Reiterated
02/07/25
Tim Anderson's Hold Rating on Bristol-Myers Squibb Due to Limited Upside and Valuation Concerns
Citi
$65
Hold
9.78%
Upside
Reiterated
02/07/25
Bristol-Myers Squibb (BMY) Gets a Hold from Citi
Cantor Fitzgerald
$50→$55
Hold
-7.11%
Downside
Reiterated
02/04/25
Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Cantor FitzgeraldShe said, "Were updating our BMY model ahead of 4Q earnings. Bristol reports on Thursday morning (2/06). Were also raising our PT to $55/share (previously $50), mostly driven by increased conviction in Cobenfy peak sales. We now model $5B in Cobenfy annual revenue at peak (2033) Key risks to our 12-month price target include: 1) faster/slower patent erosion than expected for ongoing LOEs, 2) mixed/favorable data readouts from the late-stage pipeline, 3) regulatory and commercial risks for new product launches in the coming years, and 4) broader macro themes that could put more/less pressure on the overall Biopharma sector."
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
Reiterated
03/20/25
Morgan Stanley
Reiterated
03/12/25
William Blair
Reiterated
03/11/25
Leerink Partners
Reiterated
03/10/25
Berenberg Bank
Reiterated
03/07/25
Wells Fargo
Reiterated
02/20/25
Bernstein
Reiterated
02/20/25
Truist Financial
Reiterated
02/20/25
BMO Capital
Reiterated
02/19/25
Deutsche Bank
$55→$53
Hold
-10.49%
Downside
Reiterated
02/10/25
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche BankDeutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.
Goldman Sachs
$65→$67
Buy
13.16%
Upside
Reiterated
02/07/25
Bristol-Myers Squibb Co. (BMY) PT Raised to $67 at Goldman SachsGoldman Sachs analyst Chris Shibutani raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $67.00 (from $65.00) while maintaining a Buy rating.
Bank of America Securities
$63
Hold
6.40%
Upside
Reiterated
02/07/25
Tim Anderson's Hold Rating on Bristol-Myers Squibb Due to Limited Upside and Valuation Concerns
Citi
$65
Hold
9.78%
Upside
Reiterated
02/07/25
Bristol-Myers Squibb (BMY) Gets a Hold from Citi
Cantor Fitzgerald
$50→$55
Hold
-7.11%
Downside
Reiterated
02/04/25
Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Cantor FitzgeraldShe said, "Were updating our BMY model ahead of 4Q earnings. Bristol reports on Thursday morning (2/06). Were also raising our PT to $55/share (previously $50), mostly driven by increased conviction in Cobenfy peak sales. We now model $5B in Cobenfy annual revenue at peak (2033) Key risks to our 12-month price target include: 1) faster/slower patent erosion than expected for ongoing LOEs, 2) mixed/favorable data readouts from the late-stage pipeline, 3) regulatory and commercial risks for new product launches in the coming years, and 4) broader macro themes that could put more/less pressure on the overall Biopharma sector."
BMY Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
0
0
0
0
0
Buy
12
10
12
12
11
Hold
25
22
14
15
13
Sell
8
5
4
1
2
Strong Sell
0
0
0
0
0
total
45
37
30
28
26
Each month's total comprises the sum of three months' worth of ratings.
BMY Financial Forecast
BMY Stock Forecast FAQ
What is BMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is $60.93.
What is BMY’s upside potential, based on the analysts’ average price target?
Bristol-Myers Squibb has 2.90% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BMY a Buy, Sell or Hold?
Bristol-Myers Squibb has a consensus rating of Hold which is based on 5 buy ratings, 10 hold ratings and 1 sell ratings.
What is Bristol-Myers Squibb’s price target?
The average price target for Bristol-Myers Squibb is $60.93. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $37.00. The average price target represents 2.90% Increase from the current price of $59.21.
The highest analyst price target is $70.00 ,the lowest forecast is $37.00. The average price target represents 2.90% Increase from the current price of $59.21.
What do analysts say about Bristol-Myers Squibb?
Bristol-Myers Squibb’s analyst rating consensus is a Hold. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of BMY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.